JP2016510340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510340A5 JP2016510340A5 JP2015557221A JP2015557221A JP2016510340A5 JP 2016510340 A5 JP2016510340 A5 JP 2016510340A5 JP 2015557221 A JP2015557221 A JP 2015557221A JP 2015557221 A JP2015557221 A JP 2015557221A JP 2016510340 A5 JP2016510340 A5 JP 2016510340A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cannabinoids
- affinity
- tablet
- dimethylheptyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930003827 cannabinoid Natural products 0.000 claims description 21
- 239000003557 cannabinoid Substances 0.000 claims description 21
- 229940065144 cannabinoids Drugs 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 8
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 claims description 7
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 6
- 206010039710 Scleroderma Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- YCHYFHOSGQABSW-RTBURBONSA-N (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 208000001708 Dupuytren contracture Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 206010023330 Keloid scar Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010060932 Postoperative adhesion Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000024799 Thyroid disease Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000036592 analgesia Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 208000030346 palmar fibromatosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 231100000241 scar Toxicity 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 239000003826 tablet Substances 0.000 claims 10
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 claims 6
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 4
- 239000011230 binding agent Substances 0.000 claims 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 1
- 229960003453 cannabinol Drugs 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000008119 colloidal silica Substances 0.000 claims 1
- 229960004242 dronabinol Drugs 0.000 claims 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000001826 Marfan syndrome Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002095 anti-migrative effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000002619 bicyclic group Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 229930182480 glucuronide Natural products 0.000 description 1
- 150000008134 glucuronides Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- IXAQOQZEOGMIQS-SSQFXEBMSA-M lipoxin A4(1-) Chemical compound CCCCC[C@H](O)\C=C\C=C/C=C/C=C/[C@@H](O)[C@@H](O)CCCC([O-])=O IXAQOQZEOGMIQS-SSQFXEBMSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763630P | 2013-02-12 | 2013-02-12 | |
| US61/763,630 | 2013-02-12 | ||
| US201361837743P | 2013-06-21 | 2013-06-21 | |
| US61/837,743 | 2013-06-21 | ||
| PCT/US2014/016050 WO2014127016A2 (en) | 2013-02-12 | 2014-02-12 | Ultrapure tetrahydrocannabinol-11-oic acids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178162A Division JP2019031505A (ja) | 2013-02-12 | 2018-09-22 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510340A JP2016510340A (ja) | 2016-04-07 |
| JP2016510340A5 true JP2016510340A5 (enExample) | 2017-03-16 |
| JP6689078B2 JP6689078B2 (ja) | 2020-04-28 |
Family
ID=51354671
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557221A Active JP6689078B2 (ja) | 2013-02-12 | 2014-02-12 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
| JP2018178162A Pending JP2019031505A (ja) | 2013-02-12 | 2018-09-22 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
| JP2021133797A Pending JP2021185166A (ja) | 2013-02-12 | 2021-08-19 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018178162A Pending JP2019031505A (ja) | 2013-02-12 | 2018-09-22 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
| JP2021133797A Pending JP2021185166A (ja) | 2013-02-12 | 2021-08-19 | 超高純度なテトラヒドロカンナビノール−１１−酸 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US20150141501A1 (enExample) |
| EP (2) | EP2956133A4 (enExample) |
| JP (3) | JP6689078B2 (enExample) |
| KR (2) | KR20160002709A (enExample) |
| CN (2) | CN105228613A (enExample) |
| AU (2) | AU2014216440B2 (enExample) |
| BR (1) | BR112015019180A8 (enExample) |
| CA (1) | CA2900982C (enExample) |
| WO (1) | WO2014127016A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6689078B2 (ja) | 2013-02-12 | 2020-04-28 | コーバス ファーマシューティカルズ インク． | 超高純度なテトラヒドロカンナビノール−１１−酸 |
| US20190133995A1 (en) * | 2016-04-29 | 2019-05-09 | Corbus Pharmaceuticals, Inc. | Methods for the treatment of infection |
| EP3481371A1 (en) * | 2016-07-11 | 2019-05-15 | Intec Pharma Ltd. | Oral gastroretentive formulations and uses thereof |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| US20210284621A1 (en) * | 2018-05-31 | 2021-09-16 | Corbus Pharmaceuticals, Inc. | Cannabinoids and uses thereof |
| US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| US20200121614A1 (en) * | 2018-10-18 | 2020-04-23 | Bluegrass Farmacueticals, LLC | Cannabinoid-infused transparent hydrogel skin patch |
| WO2020183456A1 (en) * | 2019-03-10 | 2020-09-17 | Bol Pharma Ltd. | Cannabinoid combinations for treating chronic pain in dialysis patients |
| JP2022551863A (ja) | 2019-10-11 | 2022-12-14 | コーバス ファーマシューティカルズ インコーポレーテッド | アジュレミン酸の組成物及びその使用 |
| US20220023253A1 (en) * | 2020-07-21 | 2022-01-27 | Np Pharma Holdings, Llc | Cannabinoid Compositions and Methods for Treating Joint Pain and Inflammation |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2186485B (en) | 1986-02-13 | 1988-09-07 | Ethical Pharma Ltd | Slow release formulation |
| US5338753A (en) | 1992-07-14 | 1994-08-16 | Sumner H. Burstein | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics |
| US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
| US8586767B2 (en) | 1999-03-22 | 2013-11-19 | Craig Rick Travis | Method for treatment of HIV and diseases of immune dysregulation |
| US6974835B2 (en) | 2000-05-17 | 2005-12-13 | Indevus Pharmaceuticals, Inc. | Methods for decreasing cell proliferation based on (3r,4r)-Δ8-tetrahydrocannabinol-11-oic acids |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| US7399872B2 (en) * | 2001-03-07 | 2008-07-15 | Webster G R Barrie | Conversion of CBD to Δ8-THC and Δ9-THC |
| AU2003302578A1 (en) * | 2002-12-04 | 2004-06-23 | Pharmos Corporation | High enantiomeric purity dexanabinol for pharmaceutical compositions |
| IL153277A0 (en) * | 2002-12-04 | 2003-07-06 | Pharmos Corp | High enantiomeric purity dexanabinol for pharmaceutical compositions |
| US7413748B2 (en) | 2002-12-13 | 2008-08-19 | Purdue Pharma L.P. | Transdermal buprenorphine to treat pain in sickle cell crisis |
| WO2004058251A1 (en) | 2002-12-19 | 2004-07-15 | University Of Massachusetts | Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators |
| US20050070596A1 (en) | 2003-05-12 | 2005-03-31 | David Baker | Methods for treatment of inflammatory diseases using CT-3 or analogs thereof |
| US20050009903A1 (en) * | 2003-06-10 | 2005-01-13 | Martin Billy R. | CB2-selective cannabinoid analogues |
| AU2006240490A1 (en) | 2005-04-21 | 2006-11-02 | Paladin Labs (Barbados) Inc. | Process for the preparation of ultrapure 4-methylprazole |
| TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| US20070037873A1 (en) | 2005-08-08 | 2007-02-15 | Zurier Robert B | Airway remodeling treatments |
| US20070060639A1 (en) | 2005-09-09 | 2007-03-15 | University Of Kentucky | Compositions and methods for intranasal delivery of tricyclic cannabinoids |
| WO2007055806A1 (en) * | 2005-10-31 | 2007-05-18 | Indevus Pharmaceuticals, Inc. | Anti-emetic uses of (3r,4r)-δ8-tetrahydrocannabinol-11-oic acids |
| GB2432312A (en) * | 2005-11-01 | 2007-05-23 | Gw Pharma Ltd | Pharmaceutical compositions for the treatment of pain |
| DK1903866T3 (en) | 2005-11-07 | 2016-07-25 | Murty Pharmaceuticals Inc | Improved release of tetrahydrocannabinol |
| US20080054300A1 (en) * | 2006-06-30 | 2008-03-06 | Philip Gene Nikkel | Body contact structure and method for the reduction of drain lag and gate lag in field effect transistors |
| US8058227B2 (en) | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| US8044071B2 (en) | 2007-10-18 | 2011-10-25 | Abbott Laboratories | Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist |
| US9192598B2 (en) | 2008-06-25 | 2015-11-24 | University Of North Texas Health Science Center At Fort Worth | Prevention of bacterial growth and biofilm formation by ligands that act on cannabinoidergic systems |
| US8877188B2 (en) | 2010-05-04 | 2014-11-04 | The Brigham And Women's Hospital, Inc. | Detection and treatment of non-dermal fibrosis |
| US20130338220A1 (en) | 2010-10-05 | 2013-12-19 | Mark Tepper | Compositions, dosages, and methods of using tetrahydrocannabinol derivatives |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| JP6689078B2 (ja) | 2013-02-12 | 2020-04-28 | コーバス ファーマシューティカルズ インク． | 超高純度なテトラヒドロカンナビノール−１１−酸 |
| US20150328198A1 (en) | 2014-05-16 | 2015-11-19 | The University Of North Carolina At Chapel Hill | Methods of treating methicillin-resistant staphylococcus aureus (mrsa) using ppar-gamma agonists |
-
2014
- 2014-02-12 JP JP2015557221A patent/JP6689078B2/ja active Active
- 2014-02-12 KR KR1020157024773A patent/KR20160002709A/ko not_active Ceased
- 2014-02-12 KR KR1020197036267A patent/KR20190139327A/ko not_active Ceased
- 2014-02-12 CN CN201480020828.1A patent/CN105228613A/zh active Pending
- 2014-02-12 CA CA2900982A patent/CA2900982C/en active Active
- 2014-02-12 CN CN201911271506.5A patent/CN110946854A/zh active Pending
- 2014-02-12 EP EP14752090.2A patent/EP2956133A4/en not_active Withdrawn
- 2014-02-12 EP EP20208635.1A patent/EP3851101A1/en not_active Withdrawn
- 2014-02-12 BR BR112015019180A patent/BR112015019180A8/pt not_active Application Discontinuation
- 2014-02-12 AU AU2014216440A patent/AU2014216440B2/en not_active Ceased
- 2014-02-12 WO PCT/US2014/016050 patent/WO2014127016A2/en not_active Ceased
- 2014-11-18 US US14/546,116 patent/US20150141501A1/en not_active Abandoned
-
2016
- 2016-07-26 US US15/220,127 patent/US10085964B2/en active Active
- 2016-11-09 US US15/347,104 patent/US9820964B2/en active Active
- 2016-11-09 US US15/347,059 patent/US9801849B2/en not_active Expired - Fee Related
-
2017
- 2017-09-07 US US15/698,544 patent/US10154986B2/en active Active
-
2018
- 2018-09-22 JP JP2018178162A patent/JP2019031505A/ja active Pending
- 2018-11-05 AU AU2018258159A patent/AU2018258159B2/en not_active Ceased
- 2018-11-21 US US16/198,381 patent/US10369131B2/en active Active
-
2019
- 2019-05-29 US US16/425,196 patent/US11052066B2/en not_active Expired - Fee Related
-
2021
- 2021-06-02 US US17/336,759 patent/US20220117931A1/en not_active Abandoned
- 2021-08-19 JP JP2021133797A patent/JP2021185166A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510340A5 (enExample) | ||
| Johnson et al. | Pharmacotherapy for amyotrophic lateral sclerosis: a review of approved and upcoming agents | |
| JP2023153783A (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
| KR101546031B1 (ko) | Ｃｍｔ 및 관련 장애를 치료하기 위한 신규 치료적 접근법 | |
| Contarini et al. | A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis | |
| CN109310769B (zh) | 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗 | |
| Chen et al. | Receptor and molecular targets for the development of novel opioid and non-opioid analgesic therapies | |
| JP6175054B2 (ja) | ヒストンアセチルトランスフェラーゼ活性剤の使用 | |
| Zhou et al. | Anti-neuroinflammatory agents for the treatment of Alzheimer’s disease | |
| Sun et al. | Chondroitin sulfate-modified tragacanth gum–gelatin composite nanocapsules loaded with curcumin nanocrystals for the treatment of arthritis | |
| Kim et al. | Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs | |
| Santoro et al. | Effect of diazoxide on Friedreich ataxia models | |
| de Souza et al. | Intraarticular monomethyl fumarate as a perspective therapy for osteoarthritis by macrophage polarization | |
| JP2004509145A (ja) | リウマチ性疾患の治療薬を製造するためのｒ−アリールプロピオン酸の使用 | |
| CN109350616B (zh) | I-brd9或其衍生物在制备抗癫痫药物中的应用 | |
| Sonvico et al. | Drug delivery to the brain: how can nanoencapsulated statins be used in the clinic? | |
| WO2007054348A1 (de) | Neue arzneimittel | |
| Zhang et al. | The role of retinoic acid receptor-related orphan receptors in skeletal diseases | |
| JP6795580B2 (ja) | 新規治療用化合物及びその治療における使用 | |
| JP6483627B2 (ja) | 脳内アミロイドβ蓄積症の予防または治療剤 | |
| JP2008508208A (ja) | 炎症性疾患の治療におけるｒｘｒアンタゴニスト | |
| EP3390347A1 (en) | Compositions of polyhydroxylated benzophenones and methods of treatment of neurodegenerative disorders | |
| CN101400255B (zh) | 用于治疗细菌、病毒、真菌疾病、炎症以及疼痛的组合物 | |
| EP3191088B1 (en) | An anticonvulsant compound | |
| Kiriaev et al. | Minocycline Treatment Reduces Mass and Force Output From Fast-Twitch Mouse Muscles and Inhibits Myosin Production in C2C12 Myotubes |